

Electronic Acknowledgement Receipt	
EFS ID:	48159861
Application Number:	12661553
International Application Number:	
Confirmation Number:	4726
Title of Invention:	Compositions and methods to prevent AAV vector aggregation
First Named Inventor/Applicant Name:	John Fraser Wright
Customer Number:	20855
Filer:	Blaine Motove Hackman/Sean Hynes
Filer Authorized By:	Blaine Motove Hackman
Attorney Docket Number:	0800-0045.01
Receipt Date:	15-JUN-2023
Filing Date:	19-MAR-2010
Time Stamp:	16:44:37
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 170
RAM confirmation Number	E20236EG45209909
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	Transmittal_Form.pdf	151032	no	1
			2b160bad89147fab7b44e26534b3e2ad932a8a2		
Warnings:					
Information:					
2	Statutory disclaimers per Manual of Patent Examining Procedure(MPEP) 1490.	Disclaimer_Form.pdf	95543	no	1
			2cf3cced215283ed11822f8379b397f79e5e08c6		
Warnings:					
Information:					
3	Power of Attorney	POA.pdf	3008783	no	1
			0ffb1675302589e4a530563cd9a11fba326ca5b2		
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	38141	no	2
			34e6b18af1c2996ee2feb892c0841e7280b72ced		
Warnings:					
Information:					
Total Files Size (in bytes):			3293499		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	12/661,553	
	Filing Date	March 19, 2010	
	First Named Inventor	John Fraser Wright	
	Art Unit	1657	
	Examiner Name	SATYENDRA K SINGH	
Total Number of Pages in This Submission		Attorney Docket Number	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Statutory Disclaimer; and Combined Power of Attorney by Assignee and Statements under 37 CFR §§ 3.73(c) and 3.71
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	DECHERT LLP		
Signature	/Amanda K. Antons/		
Printed name	Amanda K. Antons		
Date	June 15, 2023	Reg. No.	65,236

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)	
Name of Patentee <div style="text-align: center;">GENZYME CORPORATION</div>	Docket Number (Optional)
Patent Number <div style="text-align: center;">9,051,542</div>	Date Patent Issued <div style="text-align: center;">June 9, 2015</div>
Title of Invention Compositions and methods to prevent AAV vector aggregation	
<p>I hereby disclaim the following complete claims in the above identified patent: <u>1 and 2</u></p> <p>The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): <u>Reel: 39960 Frame: 0444</u></p> <p>The fee for this disclaimer is set forth in 37 CFR 1.20(d).</p> <p><input type="checkbox"/> Patentee claims small entity status. See 37 CFR 1.27.</p> <p><input type="checkbox"/> Small entity status has already been established in this case, and is still proper.</p> <p><input type="checkbox"/> A check in the amount of the fee is enclosed.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. <u>50-2778</u> .</p> <p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>	
<p>Signed at <u>Chicago</u> , State of <u>IL</u> , this <u>15th</u> day of <u>June</u> <u>2023</u> .</p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div style="width: 45%;"><p style="text-align: center;"><u>/Amanda K. Antons/</u> Signature</p><p style="text-align: center;"><u>Amanda K. Antons</u> Typed or printed name of patentee/ attorney or agent of record</p><p style="text-align: center;">DECHERT LLP - Three Bryant Park, 1095 Avenue of the Americas</p><p style="text-align: center;"><u>New York, New York 10036-6797</u> City, State, Zip Code or Foreign Country as applicable</p></div><div style="width: 45%; text-align: center;"><p><u>65,236</u> Registration Number, if applicable</p><p><u>(212) 698-3500</u> Telephone Number</p></div></div>	

**COMBINED POWER OF ATTORNEY BY ASSIGNEE
AND STATEMENTS UNDER 37 CFR §§ 3.73 (b) AND 3.71**

Genzyme Corporation (hereinafter "Assignee") having a place of business at **450 Water Street, Cambridge, Massachusetts, 02141**, states that it is the assignee of the entire right, title and interest in the patent listed below by virtue of either an assignment from the inventor(s), or by chain of title from the inventor(s), to the Assignee, recorded at the specified reel and frame numbers listed below, or attached hereto:

Patent No.	Issue Date	Title	Assignment Recordation
9,051,542	June 9, 2015	Compositions and methods to prevent AAV vector aggregation	Reel 039960 Frame 0383 Reel 039960 Frame 0444


As required by 37 CFR § 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR § 3.11.

Genzyme Corporation hereby appoints **Amanda K. Antons**, Registration No. **65,236**, and the **Dechert LLP** practitioners associated with **Customer Number 37509** as its attorneys and agents with full power of substitution and revocation, to prosecute the above-captioned patent, and to transact all business in the USPTO connected therewith, said appointment being to the exclusion of the inventor(s) and his/her attorney(s) in accordance with the provisions of 37 CFR § 3.71; provided that if any one of said attorneys or agents ceases to be affiliated with the law firm of Dechert LLP as partner, employee or of counsel, such attorney or agent's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Please direct all correspondence address for the above-identified application to:

☒ Customer Number **37509**
Dechert LLP, 1095 Avenue of the Americas, New York, NY 10036-6797
Telephone: 212.698.3500

The undersigned, whose title is supplied below, is authorized to act on behalf of the Assignee.

Assignee:	Genzyme Corporation
Date: June 14, 2023	Signed: 
	Print Name: <u>Allyson Hatton</u>
	Print Title: <u>Principal Counsel, Attorney-in-Fact on behalf of Genzyme Corporation</u>

Electronic Patent Application Fee Transmittal				
Application Number:		12661553		
Filing Date:		19-Mar-2010		
Title of Invention:		Compositions and methods to prevent AAV vector aggregation		
First Named Inventor/Applicant Name:		John Fraser Wright		
Filer:		Blaine Motove Hackman/Sean Hynes		
Attorney Docket Number:		0800-0045.01		
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
STATUTORY OR TERMINAL DISCLAIMER	1814	1	170	170
Total in USD (\$)				170